220 related articles for article (PubMed ID: 35596825)
21. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of retesting in patients with previously uninformative cancer genetics evaluations.
Dettwyler SA; Koeppe ES; Jacobs MF; Stoffel EM
Fam Cancer; 2022 Jul; 21(3):375-385. PubMed ID: 34545504
[TBL] [Abstract][Full Text] [Related]
23. Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer.
Park JS; Shin S; Lee YJ; Lee ST; Nam EJ; Han JW; Lee SH; Kim TI; Park HS
Cancer Res Treat; 2022 Oct; 54(4):1099-1110. PubMed ID: 34793666
[TBL] [Abstract][Full Text] [Related]
24. Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions.
Murray ML; Cerrato F; Bennett RL; Jarvik GP
Genet Med; 2011 Dec; 13(12):998-1005. PubMed ID: 21811163
[TBL] [Abstract][Full Text] [Related]
25. Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.
Theobald KA; Susswein LR; Marshall ML; Roberts ME; Mester JL; Speyer D; Williams RNW; Knapke SC; Solomon SR; Murphy PD; Klein RT; Hruska KS; Solomon BD
Ann Surg Oncol; 2018 Nov; 25(12):3556-3562. PubMed ID: 30167906
[TBL] [Abstract][Full Text] [Related]
26. Feasibility study of contralateral risk-reducing mastectomy with breast reconstruction for breast cancer patients with BRCA mutations in Japan.
Yoshimura A; Okumura S; Sawaki M; Hattori M; Ishiguro J; Adachi Y; Kotani H; Gondo N; Kataoka A; Iwase M; Onishi S; Sugino K; Terada M; Horisawa N; Mori M; Takaiso N; Hyodo I; Iwata H
Breast Cancer; 2018 Sep; 25(5):539-546. PubMed ID: 29520501
[TBL] [Abstract][Full Text] [Related]
27. Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors.
Graves KD; Peshkin BN; Halbert CH; DeMarco TA; Isaacs C; Schwartz MD
Breast Cancer Res Treat; 2007 Sep; 104(3):321-9. PubMed ID: 17066320
[TBL] [Abstract][Full Text] [Related]
28. A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive Italian women.
Cortesi L; Razzaboni E; Toss A; De Matteis E; Marchi I; Medici V; Tazzioli G; Andreotti A; De Santis G; Pignatti M; Federico M
Ann Oncol; 2014 Jan; 25(1):57-63. PubMed ID: 24276029
[TBL] [Abstract][Full Text] [Related]
29. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
[TBL] [Abstract][Full Text] [Related]
30. Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic.
Benusiglio PR; Korenbaum C; Vibert R; Ezenfis J; Geoffron S; Paul C; Richard S; Byrde V; Lejeune M; Guillerm E; Basset N; Lotz JP; Chabbert-Buffet N; Gligorov J; Coulet F
Eur J Med Genet; 2020 Dec; 63(12):104098. PubMed ID: 33186762
[TBL] [Abstract][Full Text] [Related]
31. What made her give up her breasts: a qualitative study on decisional considerations for contralateral prophylactic mastectomy among breast cancer survivors undergoing BRCA1/2 genetic testing.
Kwong A; Chu AT
Asian Pac J Cancer Prev; 2012; 13(5):2241-7. PubMed ID: 22901201
[TBL] [Abstract][Full Text] [Related]
32. The association between age at breast cancer diagnosis and prevalence of pathogenic variants.
Daly MB; Rosenthal E; Cummings S; Bernhisel R; Kidd J; Hughes E; Gutin A; Meek S; Slavin TP; Kurian AW
Breast Cancer Res Treat; 2023 Jun; 199(3):617-626. PubMed ID: 37084156
[TBL] [Abstract][Full Text] [Related]
33. Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients.
Woo J; Gwak G; Park I; Bae BN; Lee SK; Chae BJ; Yu J; Lee JE; Kim SW; Nam SJ; Ryu JM
Sci Rep; 2021 Jul; 11(1):14747. PubMed ID: 34285295
[TBL] [Abstract][Full Text] [Related]
34. Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study.
Wevers MR; Schmidt MK; Engelhardt EG; Verhoef S; Hooning MJ; Kriege M; Seynaeve C; Collée M; van Asperen CJ; Tollenaar RA; Koppert LB; Witkamp AJ; Rutgers EJ; Aaronson NK; Rookus MA; Ausems MG
Fam Cancer; 2015 Sep; 14(3):355-63. PubMed ID: 25700605
[TBL] [Abstract][Full Text] [Related]
35. Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients.
Isiklar AD; Aliyeva L; Yesilyurt A; Soyder A; Basaran G
Breast Cancer Res Treat; 2023 Nov; 202(2):297-304. PubMed ID: 37615792
[TBL] [Abstract][Full Text] [Related]
36. Impact of genetic counseling on the uptake of contralateral prophylactic mastectomy among younger women with breast cancer.
Terkelsen T; Rønning H; Skytte AB
Acta Oncol; 2020 Jan; 59(1):60-65. PubMed ID: 31379231
[No Abstract] [Full Text] [Related]
37. Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy.
Scott CI; Iorgulescu DG; Thorne HJ; Henderson MA; Phillips KA;
Clin Genet; 2003 Aug; 64(2):111-21. PubMed ID: 12859406
[TBL] [Abstract][Full Text] [Related]
38. Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients.
Tynan M; Peshkin BN; Isaacs C; Willey S; Valdimarsdottir HB; Nusbaum R; Hooker G; O'Neill SC; Jandorf L; Kelly SP; Heinzmann J; Kelleher S; Poggi E; Schwartz MD
Breast Cancer Res Treat; 2020 Feb; 180(1):177-185. PubMed ID: 31894446
[TBL] [Abstract][Full Text] [Related]
39. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].
Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L
Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209
[TBL] [Abstract][Full Text] [Related]
40. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
